Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Disposition and oxidative metabolism of phenylbutazone in man.

Literature DB >> 880975

Disposition and oxidative metabolism of phenylbutazone in man.

J Aarbakke, O M Bakke, E J Milde, D S Davies.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 1977 PMID： 880975 DOI： 10.1007/bf00566533

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

× No keyword cloud information.

12 in total

1. A STUDY OF STRUCTURE--ACTIVITY RELATIONSHIPS IN REGARD TO SPECIES DIFFERENCE IN THE PHENYLBUTAZONE SERIES.

Authors: J M PEREL; M M SNELL; W CHEN; P G DAYTON
Journal: Biochem Pharmacol Date: 1964-09 Impact factor: 5.858

2. Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs.

Authors: A H CONNEY; C DAVISON; R GASTEL; J J BURNS
Journal: J Pharmacol Exp Ther Date: 1960-09 Impact factor: 4.030

3. The metabolism of phenylbutazone in the rat.

Authors: O M Bakke; G H Draffan; D S Davies
Journal: Xenobiotica Date: 1974-04 Impact factor: 1.908

4. Tracer microspheres as a fecal marker in balance studies.

Authors: R H Carmichael; R E Crabtree; A S Ridolfo; A F Fasola; R L Wolen
Journal: Clin Pharmacol Ther Date: 1973 Nov-Dec Impact factor: 6.875

5. Plasma half-life of phenylbutazone in patients with impaired liver function.

Authors: E F Hvidberg; P B Andreasen; L Ranek
Journal: Clin Pharmacol Ther Date: 1974-02 Impact factor: 6.875

6. Determination of phenylbutazone in plasma.

Authors: E Jähnchen; G Levy
Journal: Clin Chem Date: 1972-09 Impact factor: 8.327

7. Individual differences in the plasma half-lives of lipid soluble drugs in man.

Authors: D S Davies; S S Thorgeirsson
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1971

8. C-glucuronides, a novel type of drug metabolites.

Authors: W J Richter; K O Alt; W Dieterle; J W Faigle; H P Kriemler; H Mory; T Winkler
Journal: Helv Chim Acta Date: 1975-12-17 Impact factor: 2.164

9. The metabolic fate of phenylbutazone (butazolidin) in man.

Authors: J J BURNS; R K ROSE; S GOODWIN; J REICHENTHAL; E C HORNING; B B BRODIE
Journal: J Pharmacol Exp Ther Date: 1955-04 Impact factor: 4.030

10. Metabolism of phenylbutazone in man.

Authors: W Dieterle; J W Faigle; F Früh; H Mory; W Theoblad; K O Alt; W J Richter
Journal: Arzneimittelforschung Date: 1976-04

15 in total

1. Increased oxidation of phenylbutazone during hydrocortisone infusion in man.

Authors: J Aarbakke; M R Bending; D S Davies
Journal: Br J Clin Pharmacol Date: 1977-10 Impact factor: 4.335

2. Specimen handling in an HPLC determination of phenylbutazone and its major metabolites in plasma, avoiding degradation of the compounds.

Authors: M J Franssen; Y Tan; I Freij; C A Van Ginneken; F W Gribnau
Journal: Pharm Weekbl Sci Date: 1986-08-22

Review 3. The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly.

Authors: K W Woodhouse; H Wynne
Journal: Clin Pharmacokinet Date: 1987-02 Impact factor: 6.447

Review 4. Assessment of the drug metabolism capacity of the liver.

Authors: B K Park
Journal: Br J Clin Pharmacol Date: 1982-11 Impact factor: 4.335

5. Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches.

Authors: Yen Low; Takeki Uehara; Yohsuke Minowa; Hiroshi Yamada; Yasuo Ohno; Tetsuro Urushidani; Alexander Sedykh; Eugene Muratov; Viktor Kuz'min; Denis Fourches; Hao Zhu; Ivan Rusyn; Alexander Tropsha
Journal: Chem Res Toxicol Date: 2011-07-21 Impact factor: 3.739